Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Anne Daub

Anne Daub is a Partner on the Therapeutics team, and joined the Firm in 2024. Prior to Deerfield, Ms. Daub was a Vice President and Biotechnology Senior Analyst for T. Rowe Price for more than five years. Before this, she was a Senior Analyst at Soros Fund Management LLC and Citadel LLC. Prior to these roles, Ms. Daub was an Analyst at Visium Asset Management for eight years and also held positions at Bear Stearns & Co., Integrated Finance Ltd. and J.P. Morgan Securities Inc. She holds a graduate degree in Finance from H.E.C Graduate School of Management in Paris, France.  

Brian Chow, Ph.D.

Brian Chow, Ph.D., is a Principal on the Therapeutics team and joined the Firm in 2022.  Prior to Deerfield, Dr. Chow spent 10 years at the University of Pennsylvania, most recently as an Associate Professor of Bioengineering. Before that, he was the Head of Research Operations and Alliances for Sage Therapeutics and a Venture Associate at Third Rock Ventures.  Dr. Chow holds a B.S. in Chemistry from Stanford University and a Ph.D. in Media Arts and Sciences from the Massachusetts Institute of Technology.

Alia Abdelhameed

Alia Abdelhameed is an Associate on the Therapeutics team. Ms. Abdelhameed joined the Firm in 2021 as a Fellow. She holds a B.E. in Biomedical Engineering with a minor in Physics from The City University of New York’s Macaulay Honors College.

Jaiti Swami

Jaiti Swami is an Analyst on the Therapeutics team. Ms. Swami joined the Firm in 2021 as a Fellow. She holds a B.E. in Biomedical Engineering from The City University of New York’s City College.

Konstantinos Aprilakis, M.D.

Konstantinos Aprilakis, M.D., is a Partner on the Therapeutics team and joined the Firm in 2021. He provides extensive research and analysis on individual companies operating in the healthcare industry. Prior to Deerfield, Dr. Aprilakis spent five years as a research analyst covering the Biotechnology sector, most recently as a Managing Director at Stifel Financial Corp. Before Stifel, Dr. Aprilakis was a Director for Deutsche Bank and a Vice President for JMP Securities. Prior to entering the finance industry, Dr. Aprilakis conducted biomedical research as a Howard Hughes Medical Institute research scholar at Stony Brook University and Weill Cornell Medical College. Dr. Aprilakis received his B.A. in Philosophy from Stony Brook University and his M.D. from Weill Cornell Medical College.

Jackson Harvey

Jackson Harvey, Ph.D., is an Analyst on the Therapeutics team and joined the Firm in 2021. Prior to Deerfield, Dr. Harvey was a research analyst at Stifel. Before Stifel, he was a Biotech Equity Research Associate for Deutsche Bank and before that, Nomura/Instinet. Dr. Harvey holds a B.S. in Biochemistry and Philosophy from Binghamton University and a Ph.D. in Pharmacology from the Weill Cornell Graduate School of Medical Sciences.

Jason Fuller, Ph.D.

Jason Fuller, Ph.D., is a Partner on the Therapeutics team and joined the Firm in 2021. Prior to Deerfield, Dr. Fuller was an investor at New Enterprise Associates (NEA), where he co-managed several investments in therapeutics, as well as in tools and diagnostics. Previous to NEA, he served as Head of Corporate Development at Jounce Therapeutics, one of several company formation projects he helped initiate in his role as Principal at Third Rock Ventures before joining Jounce. Dr. Fuller holds a B.S. in Chemical Engineering from Michigan State University, an M.Phil. from Cambridge University, and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, where he completed his degree in the lab of Robert Langer.

Joseph Pearlberg, M.D., Ph.D.

Joseph Pearlberg, M.D., Ph.D., is a Vice President of Scientific Affairs on the Therapeutics team and joined the Firm in 2017. Prior to Deerfield, Dr. Pearlberg was the Vice President of Clinical Development at Infinity Pharmaceuticals. Before Infinity Pharmaceuticals, Dr. Pearlberg worked as a Medical Director in the oncology unit of Sanofi. Dr. Pearlberg received his M.D. at the University of California, San Francisco, and completed his clinical training at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his Ph.D. in Molecular Biology from Harvard University and was a Lecturer in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He holds a B.A. in Biochemistry from the University of Pennsylvania.

Cameron Wheeler, Ph.D.

Cameron Wheeler, Ph.D., is a Partner on the Therapeutics team and joined the Firm in 2014. Prior to Deerfield, Dr. Wheeler worked for and on behalf of Eleven Biotherapeutics, Inc. as a Director since 2009. Previous to that, he was Manager of the Business Development and Operations team at Constellation Pharmaceuticals and a Senior Associate at Third Rock Ventures. Dr. Wheeler holds a Ph.D. and S.M. in Biological Engineering and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.

Howard Furst, M.D.

Howie Furst, M.D., is a Partner on the Therapeutics team and joined the Firm in 2007. Dr. Furst is a physician with eleven years of clinical experience. Prior to Deerfield, Dr. Furst was Portfolio Manager at Magnetar Capital and was responsible for building the firm’s healthcare team and developing its private and public investment approach. Before joining Magnetar, Dr. Furst served as a life sciences analyst at Maverick Capital. Dr. Furst received his B.A. with honors from the University of Pennsylvania, M.D. from New York University and M.B.A. from the Wharton School of the University of Pennsylvania.